The newest version of the heparin reversal drug, described in a recent issue of Advanced Healthcare Materials, adjusted the number of protons bound to it, making the molecule less positive so it would preferentially bind to the highly negative heparin, resulting in a much safer drug.

Complications during procedures only contributed to death in about 20% of cases.

Around 10% of all deaths following percutaneous coronary intervention are potentially preventable, a study led by Michigan Medicine finds.

Sudden cardiac arrest in young athletes: 5 things parents should know

Cardiologist shares how weight loss medications may impact cardiovascular health.

It showed high levels of accuracy at predicting death, major bleeding events and the need for blood transfusion. Visit Health Lab to read the full story. The BMC2 Probability of Events Following PCI application can be found here.

Researchers at Michigan Medicine developed an AI-driven algorithm that accurately predicts death and complications after PCI — which could emerge as a tool for clinicians as they determine treatment for blocked heart arteries.

Researchers and clinicians at the U-M Health Frankel Cardiovascular Center began sending reconditioned pacemakers to low- and middle-income countries for compassionate use cases in 2010 through the “My Heart Your Heart” program.

At Michigan Medicine, a mother of eight kids underwent a heart transplant surgery through a process called donation after circulatory death, or DCD, which saved her life.

Kyle and Kaylee Berner are enjoying making memories with their baby, Bennett, outside hospital walls. Courtesy of the Berners

Post-traumatic stress worse among Mexican American caregivers compared to white caregivers.

Itaconate shows promise in reducing inflammation for several conditions

The device would be the first clinical-grade, diagnostic wrist-worn device for long term Afib monitoring. Visit Health Lab to read the full story.

In a study of the three most commonly prescribed blood thinners, the oral anticoagulant rivaroxaban, known by the brand name Xarelto, was associated with a significantly higher risk of bleeding complications than apixaban (brand name Eliquis) and warfarin for patients with blood clots or atrial fibrillation.